Quinaprilat: a review of its pharmacokinetics, pharmacodynamics, toxicological data and clinical application

Bibliography

• Kaplan HR, Taylor DG, Olson SC, et al. Quinapril a preclinical review of the pharmacology, pharmacokinetics and toxicology. Angiology 1989;40:335-50
   PubMed Web of Science ®Google Scholar
• Pines A, Fisman EZ. ACE inhibition with moexipril:a review of potential effects beyond blood pressure control. Am J Cardiovasc Drugs 2003;3(5):351-60
   PubMedGoogle Scholar
• Breslin E, Posvar E, Neub M, et al. A pharmacodynamic and pharmakokinetic comparison of intravenous quinaprilat and oral quinapril. J Clin Pharmacol 1996;36:414-21
   PubMed Web of Science ®Google Scholar
• Olson SC, Horvath AM, Michniewicz BM, et al. The clinical pharmacokinetics of quinapril. Angiology 1989;40:351-59
   PubMed Web of Science ®Google Scholar
• Cetnarowski-Cropp AB. Quinapril: a new second-generation ACE inhibitor. DICP 1991;25(5):499-504
   PubMedGoogle Scholar
• Knütter I, Wollesky C, Kottra G, et al. Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Phamacol Exp Ther 2008;327(2):432-41
   PubMed Web of Science ®Google Scholar
• Kaplan HR, Taylor DG, Olson SC, et al. Quinapril: a preclinical review of the pharmacology, pharmacokientics, and toxicology. Angiology 1989;40:335-50
   PubMed Web of Science ®Google Scholar
• Vertes V, Haynie R. Comparative pharmacokinetics of captopril, enalapril and quinapril. Am J Cardiol 1992;69(10):8C-16C
   PubMed Web of Science ®Google Scholar
• Plosker GL, Sorkin EM. Quinapril. A reappraisal of its pharmacology and therapeutic efficacy in cardiovascular disorders. Drugs 1994;48(2):227-52
   PubMed Web of Science ®Google Scholar
• Wadworth AN, Brogden RN. Quinapril. A review of its pharmacological properties, and therapeutic efficacy in cardiovascular disorders. Drugs 1991;41(3):378-99
   PubMed Web of Science ®Google Scholar
• Ferry JJ, Horvath AM, Sedman AJ, et al. Influence of food on the pharmacokinetics of quinapril and its active diacid metabolite, CI-928. J Clin Pharmacol 1987;27(5):397-9
   PubMed Web of Science ®Google Scholar
• Accupril U.S. physician prescribing information, Pfizer, 2006. Available from: http://media.pfizer.com/files/products/uspi_accupril.pdf [Last accessed 9 June 2009]
   Google Scholar
• Blumer JL, Daniels SR, Dreyer WJ, et al. Pharmacokinetics of quinapril in children: assessment during substitution for chronic angiotensin-converting enzyme inhibitor treatment. J Clin Pharmacol 2003;43(2):128-32
   PubMed Web of Science ®Google Scholar
• Horvath A, Olson S, Ferry J, et al. Pharmacokinetics of quinapril and its active metabolite, quinaprilat, in patients with hepatic impairment. J Clin Pharmacol 1988;28:917
   Google Scholar
• Squire IB, Macfayden RJ, Lees KR, et al. Haemodynamic response and pharmacokinetics after the first dose of quinapril in patients with congestive heart failure. Br J Clin Pharmacol 1994;38(2):117-23
   PubMed Web of Science ®Google Scholar
• Begg EJ, Robson RA, Ikram H, et al. The pharmacokinetics of quinapril and quinaprilat in patients with congestive heart failure. Br J Clin Pharmacol 1994;37(3):302-4
   PubMed Web of Science ®Google Scholar
• Wolter K, Fritschka E. Pharmacokinetics and pharmacodynamics of quinaprilat after low dose quinapril in patients with terminal renal failure. Eur J Clin Pharmacol 1993;44(Suppl 1):S53-6
   PubMed Web of Science ®Google Scholar
• Yamada S, Muraoka I, Kato K, et al. Elimination kinetics of quinaprilat and perindoprilat in hypertensive patients with renal failure on haemodialysis. Biol Pharm Bull 2003;26(6):872-5
   PubMed Web of Science ®Google Scholar
• Begg EJ, Robson RA, Gardiner SJ, et al. Quinapril and its metabolite quinaprilat in human milk. Br J Clin Pharmacol 2001;51(5):478-81
   PubMed Web of Science ®Google Scholar
• Dzau VJ, Bernstein K, Celermajer D, et al. The relevance of tissue angiotensin-converting enzyme: manifestations in mechanistic and endpoint data. Am J Cardiol 2001;88(Suppl):1-20
   PubMed Web of Science ®Google Scholar
• Sedman AJ, Posvar E. Clinical pharmacology of quinapril in healthy volunteers and in patients with hypertension and congestive heart failure. Angiology 1989;40:360-9
   PubMed Web of Science ®Google Scholar
• Materson BJ. Adverse effects of angiotensin-converting enzyme inhibitors in antihypertensive therapy with focus on quinapril. Am J Cardiol 1992;69(10):46C-53C
   PubMed Web of Science ®Google Scholar
• Johnston CI, Fabris B, Yamada H, et al. Comparative studies of tissue inhibition by angiotensin converting enzyme inhibitors. J Hypertens Suppl 1989;7(5):S11-6
   PubMedGoogle Scholar
• Kinoshita A, Urata H, Bumpus M, et al. Measurement of angiotensin I converting enzyme inhibition in the heart. Circ Res 1993;73:51-60
   PubMed Web of Science ®Google Scholar
• Oosterga M, Voors AA, Buikema H, et al. Angiotensin II formation in human vasculature after chronic ACE inhibition: a prospective, randomized, placebo-controlled study. QUO VADIS investigators. Cardiovasc Drugs Ther 2000;14(1):55-60
   PubMed Web of Science ®Google Scholar
• Givertz MM. Manipulation of the renin-angiotensin system. Circulation 2001;104(5):14-8
   PubMed Web of Science ®Google Scholar
• Benetos A, Levy BI, Lacolley P, et al. Role of angiotensin II and bradykinin on aortic collagen following converting enzyme inhibition in spontaneously hypertensive rats. Arterioscler Thromb Vasc Biol 1997;17(11):3196-201
   PubMed Web of Science ®Google Scholar
• Kaplan HR, Taylor DG, Olson SC. Quinapril: overview of preclinical data. Clin Cardiol 1990;13(6 Suppl 7):VII6-12
   PubMed Web of Science ®Google Scholar
• Houben AJHM, Kroon AA, deHaan CHA, et al. Quinaprilat-induced vasodilatation in forearm vasculature of patients with essential hypertension: comparison with enalaprilat. Cardiovasc Drugs Ther 2000;14:657-63
   PubMed Web of Science ®Google Scholar
• Kobayashi N, Honda T, Yoshida K, et al. Critical role of bradykinin-eNOS and oxidative stress-LOX-1 pathway in cardiovascular remodeling under chronic angiotensin-converting enzyme inhibition. Atherosclerosis 2006;187(1):92-100
   PubMed Web of Science ®Google Scholar
• Frank GJ, Knapp LE, Olson SC, et al. Overview of quinapril, a new ACE-inhibitor. J Cardiovasc Pharmacol 1990;15(Suppl 2):S14-23
   PubMed Web of Science ®Google Scholar
• Neub M, Legler U. Pharmacokinetics of intravenous quinaprilat following rising single and multiple doses [abstract]. Naunyn Schmiedebergs Arch Pharmacol 1991;343(Suppl):R128
   PubMed Web of Science ®Google Scholar
• Culy CR, Jarvis B. Quinapril: a further update of its pharmacology and therapeutic use in cardiovascular disorders. Drugs 2002;62(2):339-85
   PubMed Web of Science ®Google Scholar
• Holtz J, Allgeier J, Goetz R, et al. Bradykinin contributes to the cardiac reparation by quinapril in rats with hypertensive left ventricular hypertrophy. Eur Heart J 1992;13(Suppl 2):252
   Google Scholar
• De Castro S, Pellicia F, Cartoni D, et al. Effects of angiotensin-converting enzyme inhibition on left ventricular geometric patterns in patients with essential hypertension. J Clin Pharmacol 1996;36(12):1141-8
   PubMed Web of Science ®Google Scholar
• Franz I-W, Tönnesmann U, Müller JFM. Time course of complete normalization of left ventricular hypertrophy during long-term antihypertensive therapy with angiotensin converting enzyme inhibition. Am J Hypertens 1998;11:631-9
   PubMed Web of Science ®Google Scholar
• Drescher T. Einfluß des ACE-Hemmers quinaprilat auf die perfusion und kontraktion des in situ schlagenden rattenherzens nach repetitiver ischämie und reperfusion. Available from: http://www.ub.uni-heidelberg.de/archiv/81 [Last accessed 9 June 2009]
   Google Scholar
• Kieback AG, Grohmann A, Baumann G, et al. Haemodynamic effects of intravenous quinaprilat in comparison to sodium nitroprusside in patients with chronic heart failure. Int J Cardiol 2007;121:102-4
   PubMed Web of Science ®Google Scholar
• Mitrovic V, Mudra H, Bonzel T, et al. Hemodynamic and hormonal effects of quinaprilat in patients with congestive heart failure. Clin Pharmacol Ther 1996;59(6):686-98
   PubMed Web of Science ®Google Scholar
• Krum H, Karrasch J, Hamer A, et al. Effect of angiotensin-converting enzyme inhibitor dosing interval on functional parameters in patients with chronic heart failure. Am Heart J 1998;135:237-41
   PubMed Web of Science ®Google Scholar
• Zi M, Carmichael N, Lye M. The effect of quinapril on functional status of elderly patients with diastolic heart failure. Cardiovasc Drugs Ther 2003;17(2):133-9
   PubMed Web of Science ®Google Scholar
• Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE inhibitor trials. JAMA 1995;273(18):1450-6
   PubMed Web of Science ®Google Scholar
• Pilote L, Abrahamowicz M, Eisenberg M, et al. Effect of different angiotensin-converting-enzyme inhibitors on mortality among elderly patients with congestive heart failure. CMAJ 2008;178(10):1303-11
   PubMed Web of Science ®Google Scholar
• van Beusekom HMM, Ferrero V, Ribichini F, et al. Quinaprilat-eluting stents do not attenuate intimal thickening following stenting in porcine coronary arteries. Atherosclerosis 2009, doi:10.1016/j.atherosclerosis.2008.11.029
   PubMedGoogle Scholar
• Pitt B, O'Neill B, Feldman R, et al. The quinapril ischemic event trial (QUIET): evaluation of chronic ace inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function. Am J Cardiol 2001;87(9):1058-63
   PubMed Web of Science ®Google Scholar
• Pepine CJ, Rouleau JL, Annis K, et al. Effects of angiotensin-converting enzyme inhibition on transient ischemia: the Quinapril Anti-Ischemia and Symptoms of Angina Reduction (QUASAR) trial. J Am Coll Cardiol 2003;42(12):2049-59
   PubMed Web of Science ®Google Scholar
• Otsuka M, Yamamoto H, Okimoto T, et al. Long-term effects of quinapril with high affinity for tissue angiotensin-converting enzyme after coronary intervention in Japanese. Am Heart J 2004;147(4):662-8
   PubMed Web of Science ®Google Scholar
• Okimoto T, Imazu M, Hayashi Y, et al. Quinapril with high affinity to tissue angiotensin-converting enzyme inhibitor reduces restenosis after percutaneous transcatheter coronary intervention. Cardiovasc Drugs Ther 2001;15(4):323-9
   PubMed Web of Science ®Google Scholar
• Kondo J, Sone T, Tsuboi H, et al. Effect of quinapril on intimal hyperplasia after coronary stenting as assessed by intravascular ultrasound. Am J Cardiol 2001;87(4):443-56
   PubMed Web of Science ®Google Scholar
• Meurice T, Bauters C, Hermant X, et al. Effect of ACE inhibitors on angiographic restenosis after coronary stenting (PARIS): a randomised, double-blind, placebo-controlled trial. Lancet 2001;357:1321-4
   PubMed Web of Science ®Google Scholar
• Ujiie Y, Hirosaka A, Mitsugi M, et al. Effects of angiotensin-converting enzyme inhibitors or an angiotensin receptor blocker in combination with aspirin and cilostazol on in-stent restenosis. Int Heart J 2006;47(2):173-84
   PubMed Web of Science ®Google Scholar
• Yamazaki T, Taniguchi I, Kurusu T, et al. Effect of amlodipine on vascular responses after coronary stenting compared with an angiotensin-converting enzyme inhibitor. Circ J 2004;68(4):328-33
   PubMed Web of Science ®Google Scholar
• Kossmehl P, Kurth E, Faramarzi S, et al. Mechanisms of apoptosis after ischemia and reperfusion: role of the renin-angiotensin system. Apoptosis 2006;11(3):347-58
   PubMed Web of Science ®Google Scholar
• Hoshida S, Yamashita N, Kawahara K, et al. Amelioration by quinapril of myocardial infarction induced by coronary occlusion/reperfusion in a rabbit model of atherosclerosis: possible mechanisms. Circulation 1999;99(3):434-40
   PubMed Web of Science ®Google Scholar
• Hu K, Gaudron P, Anders H-J, et al. Chronic effects of early started angiotensin converting enzyme inhibition and angiotensin AT1-receptor subtype blockade in rats with myocardial infarction: role of bradykinin. Cardiovasc Res 1998;39(2):401-12
   PubMed Web of Science ®Google Scholar
• Ciulla MM, Montelatici E, Ferrero S, et al. Potential advantages of cell administration on the inflammatory response compared to standard ACE inhibitor treatment in experimental myocardial infarction. J Transl Med 2008;6:30
   PubMedGoogle Scholar
• Gaudron P, Kugler I, Hu K, et al. Effect of quinapril initiated during progressive remodeling in asymptomatic patients with healed myocardial infarction. Am J Cardiol 2000;86:139-44
   PubMed Web of Science ®Google Scholar
• Oosterga M, Voors AA, Pinto YM, et al. Effects of quinapril on clinical outcome after coronary artery bypass grafting (The QUO VADIS Study). Quinapril on vascular ace and determinants of ischemia. Am J Cardiol 2001;87(5):542-6
   PubMed Web of Science ®Google Scholar
• Kwapisz MM, Müller M, Schindler E, et al. The effect of intravenous quinaprilat on plasma cytokines and hemodynamic variables during cardiac surgery. J Cardiothorac Vasc Anesth 2004;18(1):53-8
   PubMed Web of Science ®Google Scholar
• Rouleau JL, Warnica WJ, Baillot R, et al. Effects of angiotensin-converting enzyme inhibition in low-risk patients early after coronary artery bypass surgery. Circulation 2008;117(1):24-31
   PubMed Web of Science ®Google Scholar
• Ren J, Li H, Prior BM, et al. Angiotensin converting enzyme inhibition enhances collateral artery remodeling in rats with femoral artery occlusion. Am J Med Sci 2008;335(3):177-87
   PubMed Web of Science ®Google Scholar
• Schindler C, Mueller A, Bramlage P, et al. Comparison of selective AT1-receptor blockade versus ACE inhibition for restenosis prophylaxis in patients with peripheral occlusive arterial disease after stent angioplasty: a randomized, controlled, proof-of-concept study. Angiology 2007;58(6):710-6
   PubMed Web of Science ®Google Scholar
• Sen S, Kanter M, Ustundag S, et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on streptozotocin-induced diabetic nephropathy. Ren Fail 2008;30(10):1023-33
   PubMed Web of Science ®Google Scholar
• Lim SC, Koh AF, Goh SK, et al. Angiotensin receptor antagonist vs. angiotensin-converting enzyme inhibitor in Asian subjects with type 2 diabetes and albuminuria–a randomized crossover study. Diabetes Obes Metab 2007;9(4):477-82
   PubMed Web of Science ®Google Scholar
• Guiducci S, Cerinic MM. Lack of efficacy of quinapril on vascular damage in limited cutaneous systemic sclerosis. Nat Clin Pract Rheumatol 2008;4(6):288-9
   PubMedGoogle Scholar
• Gliddon AE, Doré CJ, Black CM, et al. Prevention of vascular damage in scleroderma and autoimmune Raynaud's phenomenon: a multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril. Arthritis Rheum 2007;56(11):3837-46
   PubMed Web of Science ®Google Scholar
• Gryglewski RJ, Uracz W, Swies J, et al. Comparison of endothelial pleiotropic actions of angiotensin converting enzyme inhibitors and statins. Ann NY Acad Sci 2001;947:229-45
   PubMed Web of Science ®Google Scholar
• Delli Gatti C, Osto E, Kouroedov A, et al. Pulsatile stretch induces release of angiotensin II and oxidative stress in human endothelial cells: effects of ACE inhibition and AT1 receptor antagonism. Clin Exp Hypertens 2008;30(7):616-27
   PubMed Web of Science ®Google Scholar
• Ceconi C, Francolini G, Bastianon D, et al. Differences in the effect of angiotensin-converting enzyme inhibitors on the rate of endothelial cell apoptosis: in vitro and in vivo studies. Cardiovasc Drugs Ther 2007;21(6):423-9
   PubMed Web of Science ®Google Scholar
• Hornig B, Kohler C, Drexler H. Role of bradykinin in mediating vacular effects of angiotensin-converting enzyme inhibitors in humans. Circulation 1997;95(5):1115-8
   PubMed Web of Science ®Google Scholar
• Haefeli WE, Linder L, Lüscher TF. Quinaprilat induces arterial vasodilation mediated by nitric oxide in humans. Hypertension 1997;30(4):912-7
   PubMed Web of Science ®Google Scholar
• Mancini GBJ, Henry GC, Macaya C, et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study. Circulation 1996;94(3):258-65
   PubMed Web of Science ®Google Scholar
• Kovacs I, Toth J, Tarjan J, Koller A. Correlation of flow mediated dilation with inflammatory markers in patients with impaired cardiac function. Beneficial effects of inhibition of ACE. Eur J Heart Fail 2006;8(5):451-9
   PubMed Web of Science ®Google Scholar
• Hornig B, Arakawa N, Haussmann D, et al. Differential effects of quinaprilat and enalaprilat on endothelial function of conduit arteries in patients with chronic heart failure. Circulation 1998;98:2842-8
   PubMed Web of Science ®Google Scholar
• Farkas K, Fábián E, Nagy L. Quinapril improves endothelial function in postmenopausal hypertensive patients. Kidney Blood Press Res 2008;31(4):226-33
   PubMed Web of Science ®Google Scholar
• Korkmaz H, Karaca I, Koç M, et al. Early effects of treatment with nebivolol and quinapril on endothelial function in patients with hypertension. Endothelium 2008;15(3):149-55
   PubMed Web of Science ®Google Scholar
• Steinhauff S, Pehlivanli S, Bakovic-Alt R, et al. Beneficial effects of quinaprilat on coronary vasomotor function, endothelial oxidative stress, and endothelin activation after human heart transplantation. Transplantation 2004;77(12):1859-65
   PubMed Web of Science ®Google Scholar
• Koskinen P, Manninen V, Eisalo A. Quinapril and blood lipids. Br J Clin Pharmacol 1988;26:478-80
   PubMed Web of Science ®Google Scholar
• Fogari R, Lusardi P, Megellini A, et al. Effect of antihypertensive therapy with quinapril on blood lipids. Adv Ther 1994;11(3):144-53
   Web of Science ®Google Scholar
• Undas A, Brummel-Ziedins KE, Potaczek DP, et al. Atorvastatin and quinapril inhibit blood coagulation in patients with coronary artery disease following 28 days of therapy. J Thromb Haemost 2006;4(11):2397-404
   PubMed Web of Science ®Google Scholar
• Kontopoulos AG, Athyros VG, Papageorgiou AA, et al. Effect of quinapril or metoprolol on heart rate variability in post-myocardial infarction patients. Am J Cardiol 1996;77(4):242-6
   PubMed Web of Science ®Google Scholar
• Andrews LK, Anderson JA, Kim SN, et al. Chronic toxicity evaluation of the nonsulfhydryl angiotensin converting enzyme inhibitor quinapril [abstract 729]. Toxicologist 1986;6:181
   Google Scholar
• Anderson JA, Fitzgerald JE, Jayasekaka U, et al. Preclinicla toxicological evaluation of an angiotensin II converting enzyme inhibitor of the tetrahydroquinoline series [abstract 2623]. Fed Proc 1984;43:733
   Google Scholar
• Yuan H, Feng B, Yu Y, et al. Renal organic anion transporter mediated drug-drug interaction between gemcabene and quinapril. J Pharmacol Exp Ther 2009. [Epub ahead of print]
   Google Scholar
• Dasandi B, Shah S, Shivprakash. Determination of quinapril and quinaprilat in human plasma by ultraperformance liquid chromatography-electrospray ionization mass spectometry. Biomed Chromatogr 2009;23(5):492-8
   PubMed Web of Science ®Google Scholar
• Canter D, Frank G. ACE inhibitors in the treatment of hypertension in the older patient. Eur Heart J 1990;11(Suppl D):33-43
   PubMedGoogle Scholar